Note: You clicked on an external link, which has been disabled in order to keep your shopping session open.
|Tested species reactivity||Human, Mouse, Rat|
|Host / Isotype||Rabbit / IgG|
|Immunogen||Synthetic peptide (Human) (N-terminal).|
|Purification||Antigen affinity chromatography|
|Storage buffer||PBS, pH 7.4, with 1% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C, do not freeze|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||1:100|
|Western Blot (WB)||1 µg/ml.|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
PA1-21019 detects Fas Ligand in Human, Mouse and Rat samples.
PA1-21019 has been successfully used in Immunohistochemistry (Paraffin) and Western blot procedures.
PA1-21019 immunogen corresponds to Synthetic peptide (Human) (N-terminal).
Fas ligand (FasL, CD 95L) is a type-II-membrane protein, whose N-terminus is in the cytoplasm and its C-terminal region extends into the extracellular space. Its receptor Fas (CD 95, Apo-1) is a cell-surface-type-I-membrane protein and a member of the tumor necrosis factor (TNF) and nerve growth factor (NGF) receptor family.
As a member of the TNF-cytokine family FasL induces apoptosis when interacting with its receptor Fas. FasL may exist as either membrane bound (45 kD) or soluble forms (26 kD).
The soluble protein can be released from cells upon cleavage by metalloproteinases. Binding of FasL to Fas leads to oligomerization of the receptor and triggers apoptotic cell death through the interaction of other proteins.
FasL is predominantly expressed in activated T-lymphocytes and natural killer (NK) cells also it is expressed in the tissues of immune-privilege sites such as testis and eye. FasL expression is also reported in various tissues as thymus, liver, ovary, lung, heart and kidney.
The Fas/FasL system has been shown to play a role in a number of human diseases, for example AIDS, hepatitis or cancer. It is assumed that induction of apoptosis through FasL is predominantly involved in anti-viral immune responses.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
APO1; apoptosis (APO-1) antigen ligand 1; Apoptosis (APO-1) antigen ligand 1 (Fas antigen ligand); Apoptosis antigen ligand; apoptosis antigen ligand 1; APTL; CD178; CD95 ligand; CD95-L; CD95L; CD95L protein; Fas antigen ligand; Fas Ligand; Fas ligand (TNF superfamily, member 6); Fas-LG; FasL; generalized lymphoproliferative disease; mutant tumor necrosis factor family member 6; Tumor necrosis factor (ligand) superfamily member 6 (apoptosis (APO-1) antigen ligand 1) (Fas antigen ligand); Tumor necrosis factor (ligand) superfamily, member 6 (apoptosis (APO-1) antigen ligand 1) (Fas antigen ligand); tumor necrosis factor ligand 1A; Tumor necrosis factor ligand superfamily member 6
ALPS1B; APT1LG1; APTL; CD178; CD95-L; CD95L; Fas-L; FASL; FASLG; gld; TNFSF6; TNLG1A